Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Public ClinicalTrials.gov record NCT02610127. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.
Study identification
- NCT ID
- NCT02610127
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 30, 2015 (Actual)
- Primary completion
- Jun 7, 2019 (Actual)
- Completion
- Jun 7, 2019 (Actual)
- Last update posted
- Aug 5, 2021
2015 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Health | Aurora | Colorado | 80045 | — |
| University of Florida | Gainesville | Florida | 32610 | — |
| Emory University School of Medicine | Atlanta | Georgia | 30322 | — |
| Bleeding and Clotting Disorders Institute | Peoria | Illinois | 61615 | — |
| Indiana Hemophilia and Thrombosis Center | Indianapolis | Indiana | 46260 | — |
| University of Iowa Hospitals & Clinics | Iowa City | Iowa | 52242 | — |
| Tulane University Hospital & Clinics | New Orleans | Louisiana | 70112 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Michigan State University | East Lansing | Michigan | 48823 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Comprehensive Cancer Center of Wake Forest Unversity | Winston-Salem | North Carolina | 27157 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania Health System | Philadelphia | Pennsylvania | 19104 | — |
| University of Utah Health Sciences Center | Salt Lake City | Utah | 84132 | — |
| Blood Center of Southeast Wisconsin | Milwaukee | Wisconsin | 53225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02610127, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 5, 2021 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02610127 live on ClinicalTrials.gov.